Despite recent setbacks with p53-activating small molecules including the nutlins, the cancer target keeps drug hunters coming back for more. Could immuno-oncology combinations, stapled peptides and targeted degraders unleash the therapeutic potential of the ‘guardian of the genome’? Despite recent setbacks with p53-activating small molecules including the nutlins, the cancer target keeps drug hunters coming back for more. Could immuno-oncology combinations, stapled peptides and targeted degraders unleash the therapeutic potential of the ‘guardian of the genome’?
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
大力的灵雁
缓慢怜菡
无极微光
GingerF
互助
tiptip
带头大哥
lalaland
阿瑟
xzy998
愔愔
热心市民小红花
yyy
cxw
科目三
欣慰猕猴桃
sjh
VDC
朴实夏柳
皖公网安备34019202002308
